NASDAQ:SOPH

SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

SOPHiA GENETICS logo
$6.24 -0.45 (-6.66%)
Closing price 03:58 PM Eastern
Extended Trading
$6.22 -0.02 (-0.32%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About SOPHiA GENETICS Stock (NASDAQ:SOPH)

Advanced

Key Stats

Today's Range
$6.17
▼
$6.88
50-Day Range
$6.49
▼
$8.53
52-Week Range
$3.91
▼
$8.98
Volume
694,724 shs
Average Volume
361,514 shs
Market Capitalization
$523.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Hold

Company Overview

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making.

The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.

Founded in 2011 and headquartered in Rolle, Switzerland, SOPHiA GENETICS was co-founded by Jurgi Camblong, who has served as its chief executive officer.

AI Generated. May Contain Errors.

SOPHiA GENETICS Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

SOPH MarketRank™: 
2.614446271925 of 5 stars

SOPHiA GENETICS scored higher than 52% of companies evaluated by MarketBeat, and ranked 449th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SOPHiA GENETICS has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    SOPHiA GENETICS has a consensus price target of $10.00, representing about 57.8% upside from its current price of $6.34.

  • Amount of Analyst Coverage

    SOPHiA GENETICS has only been the subject of 2 research reports in the past 90 days.

  • Read more about SOPHiA GENETICS's stock forecast and price target.
  • Earnings Growth

    Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.94) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SOPHiA GENETICS is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SOPHiA GENETICS is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SOPHiA GENETICS has a P/B Ratio of 7.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.44% of the float of SOPHiA GENETICS has been sold short.
  • Short Interest Ratio / Days to Cover

    SOPHiA GENETICS has a short interest ratio ("days to cover") of 2.62, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SOPHiA GENETICS has recently increased by 14.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    SOPHiA GENETICS does not currently pay a dividend.

  • Dividend Growth

    SOPHiA GENETICS does not have a long track record of dividend growth.

  • News Sentiment

    SOPHiA GENETICS has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for SOPHiA GENETICS this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    2 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SOPHiA GENETICS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,199,254.00 in company stock.

  • Percentage Held by Insiders

    4.88% of the stock of SOPHiA GENETICS is held by insiders.

  • Percentage Held by Institutions

    31.59% of the stock of SOPHiA GENETICS is held by institutions.

  • Read more about SOPHiA GENETICS's insider trading history.
Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SOPH Stock News Headlines

SOPHiA: 3 Key Takeaways for Long-Term Investors
SOPHiA GENETICS Earnings Call Signals Strong Momentum
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Headlines

SOPH Stock Analysis - Frequently Asked Questions

SOPHiA GENETICS's stock was trading at $4.67 at the start of the year. Since then, SOPH shares have increased by 35.7% and is now trading at $6.3360.

SOPHiA GENETICS SA (NASDAQ:SOPH) issued its earnings results on Tuesday, November, 3rd. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04. The business had revenue of $24.27 million for the quarter, compared to the consensus estimate of $24.03 million. SOPHiA GENETICS had a negative net margin of 89.18% and a negative trailing twelve-month return on equity of 128.69%.
Read the conference call transcript
.

SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering (IPO) on Wednesday, July 21st 2021. The company issued 13,000,000 shares at $17.00-$19.00 per share.

Top institutional investors of SOPHiA GENETICS include Royce & Associates LP (4.63%), AWM Investment Company Inc. (2.10%), AIGH Capital Management LLC (2.01%) and Marshall Wace LLP (0.47%). Insiders that own company stock include Jurgi Camblong, Ross Muken, Zhenyu Xu, Well Daan Van, George Cardoza, Manuela Valente, Philippe Menu, Abhimanyu Verma, Kevin Puylaert and Kathy L Hibbs.
View institutional ownership trends
.

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include NVIDIA (NVDA), Super Micro Computer (SMCI), Caribou Biosciences (CRBU), Micron Technology (MU), Advanced Micro Devices (AMD), Marvell Technology (MRVL) and Tesla (TSLA).

Company Calendar

Last Earnings
11/03/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Technology
Sub-Industry
Healthcare Technology
Current Symbol
NASDAQ:SOPH
CIK
1840706
Fax
N/A
Employees
415
Year Founded
2011

Price Target and Rating

High Price Target
$14.00
Low Price Target
$7.00
Potential Upside/Downside
+60.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79 million
Net Margins
-89.18%
Pretax Margin
-88.90%
Return on Equity
-128.69%
Return on Assets
-44.73%

Debt

Debt-to-Equity Ratio
0.70
Current Ratio
2.29
Quick Ratio
2.16

Sales & Book Value

Annual Sales
$77.27 million
Price / Sales
6.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.82 per share
Price / Book
7.60

Miscellaneous

Outstanding Shares
83,890,000
Free Float
79,801,000
Market Cap
$523.05 million
Optionable
Optionable
Beta
1.09

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:SOPH) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners